Get this delivered to your inbox, and more info about our products and services.
RBC sees nearly 30% upside for this medical tech stock as headwinds abate
The bank pointed to recent M&A success as a catalyst for the stock.
14 words~1 min read
Related reading
Bank of America sees near-40% upside in this medtech stock
BofA analysts are bullish on this German medtech name ahead of its full-year earnings report.
This biotech stock has plummeted over the past year. RBC sees big turnaround…
RBC's $22 price target implies an upside of 74% for shares of Biohaven.
This biotech stock could see a sharp swing higher after years of struggling,…
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
This biotech firm has room to run despite surging nearly 500% in past year,…
The investment bank upgraded the pharma stock to overweight from equal weight.
Is the post-earnings rally in this struggling life sciences stock for real this…
RBC analyst Conor McNamara told CNBC the wait might be a little longer.
The charts are showing this biotech stock can strengthen into year-end
David Keller breaks down the technicals on this biotech giant.